As obesity drug competition looms, Novo CEO unconcerned about margin pressure
- Country:
- United Kingdom
The benefits of obesity drugs such as Novo Nordisk's Wegovy on healthcare systems in countries such as the United States are so significant that the expected entry of rival drugs will not hurt its margins, CEO Lars Jorgensen told Reuters on Tuesday.
The Danish drugmaker raised its full-year earnings outlook earlier this month, after reporting a better-than-expected quarterly profit on diabetes treatment Ozempic.
ALSO READ
-
United States and China Vie for Lunar Base Development
-
United States Aims for World Cup Glory on Home Turf
-
India and the United States will continue to work closely for global good: PM Modi after meeting US Secretary of State.
-
The trolls come indoors as a Danish recycling artist stages his first museum exhibit
-
Russia and China scold the United States over 'Golden Dome' plans
Google News